Clinical update

Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management

Matthew G. D. Bates¹,²*, John P. Bourke², Carla Giordano³, Giulia d’Amati³, Douglass M. Turnbull¹,², and Robert W. Taylor¹*

¹Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, The Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; ²Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK; and ³Department of Radiology, Oncology and Pathology, Sapienza University, Rome, Italy

Introduction

Mitochondrial disease includes various clinical disorders that occur as a result of dysfunctional cellular oxidative phosphorylation (OXPHOS), due to a primary genetic defect. Such mitochondrial disease can be caused by defects in either mitochondrial or nuclear DNA, but mitochondrial DNA (mtDNA) mutations are the commonest cause of mitochondrial disease in adults, identified in ~70% patients, and present unique challenges in diagnosis and management. Clinical disease-based prevalence studies suggest that mtDNA disease affects 9.2/100 000 adults aged <65 years, with a further 16.5/100 000 children and adults aged <65 years at risk of development of disease.¹ These figures derive from regional referral patterns and are likely an underestimation of the true prevalence of mtDNA disease. The m.3243A>G mutation is present in ~1 in 300 of the general population and, while many individuals will possess low levels of mutation and remain asymptomatic, mtDNA disease appears more common than previously thought, causing disease in ~1 in 5000 individuals.²

The clinical spectrum in mtDNA disease is wide (Figure 1) with both isolated organ involvement and more frequent multisystem disease recognized. Presentation may be at any age and in almost any organ, but those with high energy requirements, including the brain, eye, skeletal muscle, and heart, are most frequently involved.³,⁴ Indeed natural history studies have demonstrated that cardiac involvement in mtDNA disease is progressive and an independent predictor of morbidity and early mortality.⁵,⁶ Cardiac and neurological diseases are the commonest causes of early death in patients with mitochondrial disease due to the m.3243A>G mutation, while sudden death, often with a suspected cardiac aetiology, is frequently reported.⁷ Hence, cardiologists are likely to become increasingly involved in the multi-disciplinary care of these patients. They should be familiar with the unique non-Mendelian inheritance pattern and distinctive pathophysiology,
the clinical spectrum of cardiac manifestations, and the challenges of diagnosis and management in patients with mtDNA disease.

**Clinical features**

The manifestations of mtDNA disease vary from oligosymptomatic states (e.g. type 2 diabetes mellitus or migraine) to complex syndromes often involving neurological, ophthalmological, cardiological, gastroenterological, or endocrine features. Proximal skeletal myopathy may be slowly progressive, while ophthalmological manifestations, including ptosis, ophthalmoplegia, cataracts, and optic atrophy, are common presenting symptoms. Central nervous system involvement is often associated with more severe disease, including deafness, migraine, epilepsy, ataxia, encephalopathy, stroke, or dementia. Diabetes is common in patients with mtDNA disease, while liver, renal, and other endocrinological abnormalities are more rarely described.

Clinical syndromes of mtDNA disease (Table 1), originally described in individual families, have permitted investigations of well-characterized groups of patients. However, it is now recognized that many patients with mtDNA disease do not fit into such clinical categories. Patients may present with features suggestive of mtDNA disease, such as involvement of distant organs (e.g. deafness and diabetes) or a family history of isolated organ involvement [e.g. hypertrophic cardiomyopathy (HCM)].

**Mitochondrial genetics**

Mitochondria are involved in essential cellular processes including calcium signalling, apoptosis, and generation of reactive oxygen species (ROS) but their principal function is adenosine triphosphate (ATP) synthesis via OXPHOS. The transfer of electrons between respiratory chain enzyme complexes I–IV drives proton transfer across the inner mitochondrial membrane, forming an electro-chemical gradient that is utilized by complex V to generate ATP. The mitochondrial genome encodes 22 transfer RNAs (mt-tRNAs), 2 ribosomal RNAs (mt-rRNAs), and 13 polypeptides that are all critical components of OXPHOS enzyme complexes. All other proteins involved in mitochondrial function are encoded by the nuclear genome. This bi-genomic control of the mitochondrial proteome is an important feature of mitochondrial biology.

Mitochondrial genetics are complex and display a number of unique characteristics. Multiple copies of mtDNA exist within each cell. In the general population, although a small number of mtDNA molecules may contain mutations, their
The proportion is usually so small (<1%) that the tissue can be regarded as uniform for the normal mitochondrial genome (homoplasy).7 In contrast, for most pathogenic mtDNA mutations, two or more distinct mitochondrial genomes exist within the same tissue at high percentage (heteroplasy). Most mtDNA mutations behave recessively, only manifesting when the proportion of mutated mtDNA exceeds a threshold level, typically ~60–90% (Figure 2). Tissue mtDNA mutation load and threshold may affect the onset and extent of clinical disease.12 The recognition of pathogenic homoplasmic mtDNA mutations, which frequently result in isolated organ phenotypes including cardiomyopathy, emphasizes the fact that other genetic (e.g. expression of aminoacyl tRNA synthetases) or environmental factors can modulate the phenotype.9,13,14

Human mtDNA exhibits strict maternal inheritance. Clinical disease exclusively in maternal relatives raises suspicion of mtDNA disease, and genetic counselling is manifestly different to that in nuclear genetic disorders. The nature of the defect also affects the likelihood of maternal transmission such that single, large-scale deletions are rarely transmitted from females to their offspring, while point mutations are frequently transmitted.15 Indeed, during female germline development, the number of

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Principal clinical features</th>
<th>Mitochondrial DNA mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPEO</td>
<td>External ophthalmoplegia, myopathy</td>
<td>Single or multiple mtDNA deletions</td>
</tr>
<tr>
<td>Kearns-Sayre syndrome</td>
<td>Pigmentary retinopathy, ataxia, cardiac conduction defects</td>
<td>Single, large-scale mtDNA deletion</td>
</tr>
<tr>
<td>Leigh syndrome</td>
<td>Subacute necrotizing encephalopathy, basal ganglia lesions</td>
<td>Complex I, IV, and V gene mutations</td>
</tr>
<tr>
<td>LHON</td>
<td>Acute or sub-acute visual loss</td>
<td>Complex I gene mutations</td>
</tr>
<tr>
<td>MELAS</td>
<td>Myopathy, encephalopathy, lactic acidosis, stroke-like episodes</td>
<td>mt-tRNA gene mutations</td>
</tr>
<tr>
<td>MERRF</td>
<td>Myoclonus, epilepsy, ataxia</td>
<td>mt-tRNA gene mutations</td>
</tr>
<tr>
<td>NARP</td>
<td>Neuropathy, ataxia, pigmentary retinopathy</td>
<td>Complex V mutations</td>
</tr>
<tr>
<td>Pearson’s marrow-pancreas syndrome</td>
<td>Sideroblastic anaemia, exocrine pancreatic insufficiency, hepatopathy, nephropathy</td>
<td>Single, large-scale mtDNA deletion</td>
</tr>
</tbody>
</table>

CPEO, chronic progressive external ophthalmoplegia; LHON, Leber’s hereditary optic neuropathy; MELAS, myopathy, encephalopathy, and lactic acidosis with stroke-like episodes; MERRF, mitochondrial encephalopathy with ragged red fibres; mtDNA, mitochondrial DNA; NARP, neurogenic ataxia and retinitis pigmentosa.

Figure 2 Mitochondrial DNA mutations and patterns of cellular respiratory function. (A) In normal individuals, all cardiomyocytes contain multiple copies of wild-type mitochondrial DNA (black circles, upper panel), with sequential cytochrome c oxidase/succinate dehydrogenase histochemistry showing all cardiomyocytes as cytochrome c oxidase-positive (brown, lower panel). (B) In patients with heteroplasmic mitochondrial DNA mutations, different proportions of wild-type (black) and mutated mitochondrial DNA (red) are present in individual cardiomyocytes (upper panel); cytochrome c oxidase/succinate dehydrogenase histochemistry reveals a mosaic pattern of cytochrome c oxidase-deficient and cytochrome c oxidase-positive cardiomyocytes, with cellular respiratory deficiency only apparent when a threshold proportion of mutated mitochondrial DNA is reached (lower panel). (C) In patients with homoplasmic mitochondrial DNA mutations, all cardiomyocytes contain multiple copies of mutated mitochondrial DNA (red, upper panel), with the majority of cells displaying cytochrome c oxidase deficiency (blue, lower panel).
mtDNA molecules within each oocyte is dramatically reduced before being re-amplified to a final number >100,000. This 'genetic bottleneck' accounts for shifts in mtDNA mutation load between generations and partly explains variations in clinical disease severity.\(^6\)

The mitochondrial genome acquires mutations at a rate 10–17-fold higher than nuclear DNA due to proximity to the OXPHOS system and deficiency in DNA repair mechanisms.\(^4\) Owing to the continuous replicative nature of mtDNA, the proportion of mutated mtDNA molecules can be increased by clonal expansion, even in post-mitotic cells including cardiomyocytes.\(^7\) Although the clinical importance of these acquired mtDNA mutations in the general population is debated, in patients possessing high levels of a mtDNA mutation, this process can lead to profound changes in mtDNA mutation load and contribute to clinical progression.

### Cardiac disease

More than 250 different pathogenic mtDNA mutations have been reported in humans, many in association with cardiac disease, which ranges from cardiomyopathy to electropathy, including conduction disease and ventricular pre-excitation. This diversity and the absence of a cardiac phenotype that is unique to patients with mtDNA disease present challenges to the cardiologist.

### Prevalence and natural history

The true prevalence of mtDNA-related cardiomyopathy is unknown although, based on the prevalence of mtDNA disease and the frequency of cardiac involvement, at least \(~1\) in 10–15,000 of the general population will be affected. Public databases of mtDNA mutations associated with human disease exist and will be an important resource in determining prevalence.\(^18\,19\) However, such databases are currently not completely accurate as, owing to extensive variability of the mitochondrial genome and a lack of adherence to strict canonical criteria for determining pathogenicity, some non-disease causing variants are listed. Challenges lie ahead with regard to the analysis of such bio-informatic data.\(^20\,22\)

Natural history studies have demonstrated both the high prevalence of cardiac disease and the deleterious effects on patient outcome of a cardiac presentation. A significant difference in survival to age 16 years was noted in 113 children with mitochondrial disease (18 and 92\%, respectively, in those with and without cardiomyopathy).\(^6\) This result, in a cohort including patients with mitochondrial and nuclear DNA mutations, has subsequently been confirmed in other large paediatric cohorts.\(^23\,24\) Adult studies, in patients with mtDNA mutations exclusively, have established the progressive nature of cardiac involvement,\(^8,25,26\) with important impacts on morbidity and early mortality.\(^7,27\) In common with many newly recognized disorders, early reports of cardiac involvement in mtDNA disease featured patients with severe phenotypes. Family genetic screening has undoubtedly broadened the spectrum of mtDNA disease to include more asymptomatic or oligosymptomatic adults, perhaps limiting the applicability of early studies. A recent study of 32 adult patients demonstrated that, although cardiac involvement was apparent in 78\% patients, minor electrocardiogram (ECG) abnormalities represented the most common manifestation, with cardiomyopathy present in 25\% patients.\(^5\) Progressive systolic dysfunction and high-grade atrioventricular (AV) block did occur in a minority but the incidence of severe cardiovascular complications was relatively low over a median follow-up of 4 years. Large multi-centre prospective clinical cohort studies are underway and will provide novel insights into the natural history and response to intervention of adult mtDNA disease.

### Pathogenetic mechanisms

The molecular events linking mtDNA defects to cardiac dysfunction are poorly understood. Although several factors, including rarity of the disorder, limited access to human cardiac tissue and an absence of reliable animal models of mtDNA disease play a role in limiting investigation, the weak nature of genotype–phenotype correlations is a critical factor. The development of cardiomyocyte cell lines from patients with mtDNA disease using inducible pluripotent stem cell technology will undoubtedly be an important step forward in this area.

Early mechanistic insights developed from observation of patterns of disease. Although patients with specific mtDNA mutations may present with different cardiac phenotypes,\(^25,28\) and similar cardiac involvement can occur in patients with different mtDNA mutations,\(^25,28\) cross-sectional studies suggest patterns of cardiac involvement do exist (Table 2). For example, cardiomyopathies, often with a hypertrophic phenotype, are more frequently reported in association with mt-tRNA gene mutations, while AV block is a feature of Kearns-Sayre syndrome (KSS), which is commonly caused by single, large-scale deletions in mtDNA.\(^3\) The only cardiac phenotype reported in association with the m.1555A>G mt-rRNA gene mutation is a restrictive cardiomyopathy.\(^29\) Although differential effects of mutations in mt-tRNA, mt-rRNA, and polypeptide genes on mitochondrial transcription, translation, and protein function may be expected, the mechanisms underlying this apparent genotype–phenotype relationship are unclear. Tissue specificity of mutation load is widely recognized as a factor in the diverse clinical features of mtDNA disease generally; a similar phenomenon occurring within, rather than between, tissues may be equally important. Higher mutation load of a single, large-scale mtDNA deletion has been reported in post-mortem AV nodal and His-Purkinje system tissue than in contractile myocardium from a patient with KSS, suggesting a reason for the apparent sensitivity of the conduction system.\(^30\)

Marked induction of mitochondrial biogenesis is a prominent feature of end-stage mtDNA-related cardiomyopathy,\(^31\,33\) and has been demonstrated in diverse tissues from patients with mtDNA disease. Although in skeletal muscle this response can partially compensate for OXPHOS dysfunction, experimental, and clinical evidence suggests that it may have a detrimental effect in cardiac muscle.\(^34,35\) Proliferation of intermyofibrillar mitochondria mechanically interferes with sarcomeric function, contributing to adverse cardiac remodelling.\(^32,34\) Induction of genes involved in mitochondrial biogenesis and fatty acid oxidation (FAO) in mtDNA-related cardiomyopathy increases oxygen consumption and contrasts with other pathologies, including left ventricular hypertrophy (LVH), where cardiac energy metabolism shifts from FAO to glucose oxidation to reduce oxygen consumption.\(^36\)
Moreover, in the absence of induction of antioxidants, an increased mass of mutated mitochondria causes increased ROS. The pathogenetic role of ROS has been confirmed in animal models of nuclear mitochondrial disease, but data on mtDNA disease are lacking.

Cardiomyopathy

Hypertrophic cardiomyopathy/left ventricular hypertrophy

Hypertrophic remodelling is the dominant pattern of cardiomyopathy in all forms of mitochondrial disease, occurring in up to ~40% patients, and can mimic HCM. The prevalence of HCM within the general population is ~1 in 500 yet sarcomeric protein mutations are identified in only ~60% of HCM patients. mtDNA-related cardiomyopathy represents a potential phenotype of HCM and may partly account for this discrepancy similar to single gene disorders that have already been identified in HCM cohorts such as Anderson-Fabry and glycogen storage diseases. Cardiologists should be alert to the presence of extra-cardiac features (Figure 1), or possible maternal inheritance patterns, in this population.

Point mutations in mtDNA can cause sporadic or maternally inherited cardiomyopathy, which may be the only or presenting feature. Recent cohort studies using echocardiography have identified LVH in 38–56% patients harbouring the m.3243A>G mutation and have revealed a correlation between skeletal muscle mutant load and indexed left ventricular mass. Patients with high mutation load may therefore be at increased risk of development of cardiomyopathy. Left ventricular hypertrophy is recognized in patients with other mtDNA mutations including several mt-tRNA genes (e.g. m.8344A>G in MTTK, m.4269A>G and m.4317A>G in MTTL1) and infrequent polypeptide genes (e.g.

<table>
<thead>
<tr>
<th>Gene</th>
<th>mtDNA mutation</th>
<th>Electropathy</th>
<th>Cardiomyopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Ventricular pre-excitation</td>
<td>Conduction disease</td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTTL1</td>
<td>m.3243A&gt;G</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>MTTI</td>
<td>m.3430A&gt;G</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>MTTK</td>
<td>m.8344A&gt;G</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>MTND4</td>
<td>m.11778G&gt;A</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>single, large-scale mtDNA deletion</td>
<td>–</td>
<td>++</td>
</tr>
</tbody>
</table>

Pathogenic mitochondrial DNA mutations were identified from a search of online databases, together with the cumulative experience of the authors, excluding rare single nucleotide polymorphisms, and haplogroup markers. mtDNA, mitochondrial DNA; +, reported in cross-sectional cohort study with ≥10% frequency; –, reported in single case report(s)/family series only; –, not reported.

Table 2  Cardiac phenotypes associated with pathogenic mtDNA mutations
Indeed the mt-tRNA genes appear to be a particularly sensitive location in the mitochondrial genome for mutations associated with the hypertrophic phenotype (Table 2). Although LVH is reported in patients with mitochondrial disease due to mutations in genes encoding mt-rRNAs and polypeptides, it appears to be a much less common clinical finding in this subset of patients than in patients with mt-tRNA gene mutations. Homoplasmic mtDNA mutations, which characteristically cause organ-specific phenotypes, have also been reported in patients with cardiac disease.9–14 The homoplasmic m.4300A>G mutation, in the mt-tRNA gene (MTT1) gene has now been identified in several families with isolated mtDNA-related cardiomyopathy and may play a more important role in inherited cardiomyopathy than previously appreciated, although this is yet to be confirmed through systematic analysis of HCM cohorts.9

There are important differences in the cardiac phenotype and natural history of HCM and mtDNA-related cardiomyopathy. Left ventricular outflow tract (LVOT) obstruction is rarely observed in mtDNA-related cardiomyopathy, yet it appears that the likelihood of progression to ventricular dilation and heart failure is higher than in HCM.41 A longitudinal study with 6.9 years mean follow-up duration demonstrated that the degree of LVH correlated positively with chamber dilation and negatively with systolic function in patients harbouring the m.3243A>G mutation.26 Heart failure with ventricular dilation and impaired systolic function has been reported in patients with LVH and the m.3243A>G or m.8344A>G mutations.25,26

Dilated cardiomyopathy

Although dilated cardiomyopathy (DCM) can be the initial pattern of cardiac involvement in mtDNA disease,48 it more commonly represents progression of pre-existing hypertrophy with chamber dilation and systolic dysfunction.25,49,50 One patient with DCM was identified among 17 patients with mitochondrial disease, while a recent study of 18 patients with the m.8344A>G mutation confirmed DCM in 22% patients.25,27 Dilated cardiomyopathy is rarer than the hypertrophic phenotype in association with other mt-tRNA point mutations, including m.3243A>G, m.4269A>G, m.4317A>G, and m.4317A>G mutation with a m.8528T>G and m.8344A>G mutations appears to be an infrequent and late phenomenon in KSS, described in only 2% of published patients.51,52

Due primarily to phenotypic rarity, data are lacking concerning natural history in patients with mtDNA disease and DCM phenotype. Mouse models of DCM and mitochondrial disease do exist,39,53,54 but do not feature mtDNA point mutations or single deletions and have little direct relevance to patients with these specific mutations. Cardiac symptoms may be limited in patients with multisystem mtDNA disease due to progressive skeletal myopathy restricting physical activity. However, limited echocardiographic studies in adults suggest that progression of DCM may be slow and, at least in some patients, responsive to conventional heart failure therapies.25,48

Rarer cardiomyopathies

Restrictive cardiomyopathy is a rare presentation of cardiac involvement in mtDNA disease but has been reported in association with maternally inherited deafness and diabetes due to the m.3243A>G mutation55 and as the only clinical finding in a subject with the m.1555A>G mutation.29

Left ventricular non-compaction (LVNC) is caused by abnormal compaction of myofibrils during cardiac development and results in progressive ventricular dilatation and systolic dysfunction. Differentiation from normal variants can be difficult, diagnosis remains controversial, and the natural history is unclear.56,57 Mutations in sarcomeric or ion channel genes account for only a small proportion of LVNC cases.58 Left ventricular non-compaction has recently been recognized as a cardiac manifestation of mtDNA disease, particularly in paediatric populations, and most commonly as part of multisystem disease.6–59 A recent report of an association between a m.3398T>C MTND1 variant and LVNC supports the assertion that mtDNA mutations may be important in pathogenesis.60

Histiocytoid cardiomyopathy is another rare cardiomyopathy characterized by pathognomonic histiocyte-like cells within the subendocardium. Reported cases frequently document aggregates of structurally abnormal mitochondria,61 and have been linked to the m.8344A>G mutation and a mutation in the MTCYB gene that encodes an complex III enzyme subunit.62,63

Electropathy

Conduction system disease and bradyarrhythmias

Conduction system disease occurs commonly in patients with mtDNA disease, and prevalence increases with age as in the general population. Atrio-ventricular block forms part of the diagnostic criteria of KSS such that a review of the published literature suggests a prevalence of conduction system disease of 84%.51 Conduction system disease occurs, albeit less commonly, in ~5–10% of patients in other forms of mtDNA disease with AV or intra-ventricular conduction disturbances reported in association with the m.3243A>G and m.8344A>G mutations.25,28 Although mechanisms are currently unknown, differences in mutation load or in sensitivity of different cardiac cell types to different mtDNA mutations (threshold) may account for this phenotypic discrepancy.50

Importantly in patients with neuromuscular disease, including mtDNA disease, progression to high-grade AV block is often unpredictable necessitating prompt recognition of any conduction system disease and consideration of early intervention.64,65 Early deaths in patients with KSS may be directly attributable to infra-nodal heart block.66 Risks of progression and clinical outcomes associated with conduction system disease in other forms of mtDNA disease are unknown.

Ventricular pre-excitation and tachyarrhythmias

Ventricular pre-excitation and Wolff–Parkinson–White syndrome may be more common in patients with mtDNA disease than in the general population. First observed in association with Leber’s hereditary optic neuropathy, ventricular pre-excitation has been reported in 10% patients and 8% maternal relatives compared with 1.6% of paternal relatives.67 Although supported by several studies, the failure of some groups to replicate this finding has stimulated debate as to whether these results represent chance findings or evidence of a direct aetiological link.40 Evidence in support...
of the latter is provided by reports of ventricular pre-excitation occurring in association with the m.8344A>G and m.3243A>G mutations, where manifest pre-excitation was observed in 3–27% of patients. Although ventricular pre-excitation has been reported in association with mtDNA-related cardiomyopathy, this combination does not appear as common as in other forms of inherited disease such as that caused by PRKAG2 gene mutations. Symptomatic patients with mtDNA disease and manifest ventricular pre-excitation have undergone successful radio-frequency ablation (RFA) of accessory pathways, but natural history remains unclear and invasive management of asymptomatic patients is controversial.

Supraventricular and ventricular tachyarrhythmias have both been reported in patients with mtDNA disease, particularly in children and in those with cardiomyopathy. Although prolongation of the QT interval has been identified in some patient groups, determination of the true incidence of this finding and the risk of ventricular arrhythmia requires larger longitudinal studies.

Diagnosis

The diagnosis of mtDNA disease is complex and requires a multi-disciplinary approach (Figure 3). A maternal inheritance pattern or the presence of extra-cardiac features of mtDNA disease may raise suspicion of the diagnosis. Although these extra-cardiac manifestations include common or non-specific features (Figure 1), particular patterns of organ involvement (e.g. diabetes and deafness) should alert the cardiologist to the possibility of mtDNA disease.

Molecular genetic testing

Emerging evidence supports screening of peripheral lymphocytes or urine samples for mtDNA mutations (e.g. 3243A>G, m.4300A>G) in specific clinical scenarios. In patients with unexplained LVH not fulfilling standard criteria for HCM, symmetrical hypertrophy and the absence of LVOT obstruction may favour an alternative diagnosis, such as mtDNA-related cardiomyopathy. Sequencing of the mitochondrial genome may be an appropriate next step in investigation. However, with more pronounced variation than the nuclear genome, challenges exist in the determination of pathogenesis. Comparison with published databases is necessary but true determination of the pathogenicity of novel mtDNA mutations is complex and reliant on canonical criteria involving segregation of mutation within tissues and families, evolutionary conservation of affected nucleotides or amino acids, and occasionally biochemical studies in cultured cells.

Invasive biopsy analysis

Although molecular genetic testing may expedite diagnosis of mitochondrial disease in some patients, in many, particularly those with novel mutations, analysis of invasive biopsy tissue remains important. Pathological studies of the myocardium are available from a small number of patients with mtDNA-related cardiomyopathy. Common but relatively non-specific histological findings are diffuse cellular hypertrophy with swollen, often vacuolated, cardiomyocytes (Figure 4). Interstitial fibrosis varies but myofibre disarray, typical of HCM, is absent and ultrastructural examination reveals proliferation of abnormal mitochondria with sarcomere displacement.

Cardiac investigations

Cardiac involvement in mtDNA disease can remain asymptomatic until an advanced stage is reached, often due to limited mobility of patients. Although the utility of screening is debated in mtDNA disease given variability in clinical course, best practice supports a high index of suspicion and instigation of regular surveillance. Multi-disciplinary care is essential given potential involvement of organs that can cause symptoms associated with cardiac disease. Exercise intolerance, for example, may result from skeletal myopathy or respiratory muscle weakness, as well as cardiomyopathy or arrhythmia. A cardiologist with an understanding of mtDNA disease should be involved in the care of all patients with confirmed cardiac involvement (Figure 5).

In common with a number of other rare neuromuscular or metabolic conditions, there are few clear recommendations for management. There is general agreement that all patients with mtDNA disease, unaffected carriers of a known mutation, and obligate carriers should have baseline cardiac assessment. This should include clinical history and examination, 12-lead ECG and an assessment of cardiac structure and function, typically echocardiography, as a minimum standard in all forms of mtDNA disease as, although specific cardiac phenotypes are associated with different mtDNA mutations (e.g. single, large-scale mtDNA deletion and AV block), diverse cardiac phenotypes can occur. Although the initiation, nature, and frequency of cardiac screening has not been subject to specific study, many experienced centres use an initial 12-month interval for repeated ECG and functional assessments, consistent with guidelines for HCM and different forms of neuromuscular disease, with extension of this interval to 3–5 years if normal findings are repeated (Figure 5). Magnetic resonance imaging (MRI) may reveal cardiac involvement when standard evaluation is unremarkable, and permits imaging without reliance on acoustic windows, often absent in patients with skeletal or respiratory muscle disease. Cardiac MRI also permits accurate tissue characterization using late gadolinium enhancement, an area where ongoing studies may reveal important features of mtDNA-related cardiomyopathy. Several lines of
Evidence suggests a central role of disrupted energy metabolism in HCM and phenocopies, including mtDNA disease. Abnormal cardiac bioenergetics have been demonstrated in patients with m.3243A>G mutation and structurally normal hearts on echocardiography. Contemporaneous assessments of myocardial bioenergetics, fibrosis, and myocardial deformation, using cardiac tagging may permit early identification of patients at risk of developing cardiomyopathy. The preferred approach may therefore involve both cardiac MRI and echocardiography at diagnosis to establish a baseline, with subsequent screening performed with echocardiography alone. However, larger longitudinal studies are necessary to clarify the role of such investigations in patients with mtDNA disease.

**Management**

Although clinical trials are underway, a recent Cochrane review suggests that there is no current drug treatment that has shown...
clear clinical benefit in the primary outcome in patients with mtDNA disease. Resistance and endurance exercise training programmes both improve symptoms in mtDNA disease but effects on cardiac structure and function are currently unknown, and benefits are lost on cessation of exercise with deconditioning. Patients with mtDNA disease remain at risk of common acquired cardiac disorders and current guidelines to address conventional risk factors should be followed.

Cardiomyopathy

Recommendations for the management of hypertrophic remodelling in mtDNA disease are reliant on clinical studies in HCM and LVH, with interventions based on reasonable clinical assumptions of similar treatment effects, together with reports of successful outcomes. Non-dihydropyridine calcium channel antagonists and β-blockers are recommended in symptomatic patients or those with asymptomatic severe LVH in HCM. β-blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers have been demonstrated to reduce LVH in the general population. Given the progressive nature of hypertrophic remodelling in mtDNA disease, these drugs are often started with the first appreciation of LVH.

Standard optimal medical therapies for heart failure with systolic dysfunction are used in mtDNA disease, with reports of both clinical improvement and progression despite therapy. Angiotensin-converting enzyme inhibitors have been shown to slow the onset and progression of cardiomyopathy associated with Duchenne muscular dystrophy, and reduce mortality. Complex device therapy including the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy should be considered in patients with mtDNA disease provided conventional guidelines are met, including life expectancy of >1 year. Cardiac transplantation, although controversial in metabolic disease with potential multisystem involvement, has been performed successfully in patients with mtDNA disease. Clinical outcomes appear to be dependent on the extent of extra-cardiac involvement in addition to complications of transplantation itself, although data are lacking.

Electropathy

International guidelines recommend permanent pacemaker (PPM) implantation at an earlier stage of conduction system dysfunction in patients with neuromuscular disease, including mtDNA disease, than in the general population due to unpredictable progression. In patients with neuromuscular disease, any degree
of AV block, including first-degree block, and/or any degree of fascicular block are class IIb indications for PPM implantation, irrespective of symptoms. Such prophylactic PPM implantation, however, remains controversial. Severe surface ECG abnormalities (PR interval >240 ms, QRS duration >120 ms, rhythm other than sinus, or high-grade AV block) and an HV interval >70 ms are high-risk features for sudden death in myotonic dystrophy. \footnote{92,93} Recent evidence suggests that an invasive strategy to assess AV conduction in those with high-risk non-invasive features is associated with improved survival. \footnote{94} Many centres use similar criteria.
in patients with mtDNA disease, particularly KSS. Although sudden deaths have been reported in patients with functioning PPMs and a variety of neuromuscular diseases, there are no data to guide ICD implantation in patients with mtDNA disease out with standard primary and secondary indications.

Conventional medications for symptomatic supraventricular arrhythmias can be used in patients with mtDNA disease. Ventricular pre-excitation can lead to symptomatic re-entrant tachyarrhythmia in patients with mtDNA disease and is, in other patients, associated with a small risk of sudden cardiac death. Consistent with international guidelines, and following non-invasive assessment including an exercise ECG, consideration should therefore be given to invasive electrophysiological study (EPS) in all patients with mtDNA disease and non-intermittent pre-excitation. Asymptomatic pre-excitation is a class Ill indication for EPS ± RFA in adults and class IIb in children >5 years of age, but class III (i.e. not indicated) in those <5 years of age.

Conclusions

Cardiac involvement in mtDNA disease is common and is an important predictor of morbidity and early mortality. Specific disease-modifying therapies do not yet exist, and data are scarce concerning natural history, screening, and management. Comprehensive clinical algorithms for cardiac disease are vitally needed, and considerable international collaborative efforts will be required to achieve this aim. Nevertheless, cardiologists will become more involved in the care of patients with mtDNA disease as recognition of these disorders increases. Appreciation of the clinical spectrum of cardiac involvement in mtDNA disease and risks of disease progression will enable appropriate input to the multi-disciplinary care of patients.

Funding

This work was supported by the Wellcome Trust (BH092142 to M.G.D.B., 096919Z/11/Z and 074454/Z/04/Z to D.M.T. and R.W.T.); and the Newcastle upon Tyne Hospitals NHS Foundation Trust and NHS Specialized Services that support the D.M.T. and R.W.T.); and the Newcastle upon Tyne Hospitals NHS Foundation Trust and NHS Specialized Services that support the David and Victoria Evans Trust (BH092142 to M.G.D.B., 096919Z/11/Z and 074454/Z/04/Z to D.M.T. and R.W.T.). This work was supported by the Wellcome Trust (BH092142 to M.G.D.B., 096919Z/11/Z and 074454/Z/04/Z to D.M.T. and R.W.T.).

References

Heddi A, Stepien G, Benke PJ, Wallace DC. Coordinate induction of energy gene
Sebastiani M, Giordano C, Nediani C, Travaglini C, Borchi E, Zani M, Feccia M,
Wredenberg A, Wibom R, Wilhelmsson H, Graff C, Wiener HH, Burden SJ,
Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism
Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM. Preva-
Dai DF, Chen T, Wanagat J, Laflamme M, Marcinek DJ, Emond MJ, Ngo CP,
Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
Schoonderwoerd K, van den Bosch BJC, Smeets HJM, Geleijnse ML. Cardiac in-
Andreu A, Checcarelli N, Iwata S, Shanske S, DiMauro S. A missense mutation in
Roberts NK, Perloff JK, Kark RA. Cardiac conduction in the Kearns-Sayre syn-
Nikoskelainen E, Savontaus M, Huoponen K, Antila K, Hartiala J. Pre-excitation
Finsterer J, Stollberger C, Kopsa W, Jaksch M. Wolff-Parkinson-White syndrome
M.G.D. Bates et al.

30. Muller-Hocker J, Jacob U, Seibel P. The common 4977 base pair deletion of mito-
32. Sebastiani M, Giordano C, Nediani C, Travaglini C, Borchi E, Zani M, Feccia M, 
34. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism
36. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism
37. Daif DF, Chen T, Wanagat J, Laflamme M, Marcinek DJ, Emond MJ, Ngo CP,
39. Dai DF, Chen T, Wanagat J, Laflamme M, Marcinek DJ, Emond MJ, Ngo CP,
40. Dai DF, Chen T, Wanagat J, Laflamme M, Marcinek DJ, Emond MJ, Ngo CP,
41. Dai DF, Chen T, Wanagat J, Laflamme M, Marcinek DJ, Emond MJ, Ngo CP,
42. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
43. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
44. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
45. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
46. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
47. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
48. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
49. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
50. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
51. Hirano M, DiMauro S. Clinical features of mitochondrial myopathies and encepha-
52. Tveskov C, Angelo-Nielsen K. Kearns-Sayre syndrome and dilated cardiomyop-
53. Hirano M, DiMauro S. Clinical features of mitochondrial myopathies and encepha-
54. Narula N, Zaragoza MV, Sengupta PP, Li P, Haider N, Verjans J, Waymire K, 
55. Watanabe SM, El-Hassan N, Kahler SG, Zhang Q, Ma YW, Miller E, Wong B, 
62. Vallance HD, Jeven G, Wallace DC, Brown MD. A case of sporadic infantile histio-
66. Roberts NK, Perloff JK, Kark RA. Cardiac conduction in the Kearns-Sayre syn-


